Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids
- PMID:27411392
- DOI: 10.2174/1567201813666160712164149
Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids
Abstract
Background: The aim of this study is to evaluate the possible advantages of liposomes with high transition temperature (Tm) in the function of a vaccine for P5 HER2/neu-generated peptide and its adjuvant action to elicit CD8+ T cell response and its efficacy in TUBO in vivo tumor mice model, which over expresses the HER2/neu oncogene. P5, a hydrophobic peptide, was encapsulated in the nanoliposomes consisting of DSPC/DSPG/Chol(Tm 54°C) with a chaotropic loading system via 7M urea and described by size, zeta potential, encapsulation efficiency, and the structural stability of SDS-PAGE.
Methods: We immunized the mice for three times subcutaneously based on a two-week intervals using encapsulated peptide in the nanoliposomes, empty liposome, P5 in PBS, and PBS. Enzyme-linked immunospot assay, cytotoxicity test, and flow cytometric studies followed by the size of tumor and survival time measurements, which were done in TUBO tumor mice version.
Results: Findings of ELISpot and flow cytometric analysis showed that immunization with Lip-p5 nanoliposomes has enhanced the antigen-specific IFN-γ response of CD8+ T cells and induced CTL response, which resulted in a smaller tumor and longer survival time. In addition to increase in amounts of IFN-γ-CD8+ T cells in a group, which was immunized with Lip-P5, our findings also revealed a Th1 shift in the group immunized with an empty liposome with reduced frequencies of IL-4-producing cells and increase of IFN-γ-producing cells.
Conclusion: The results indicated that simple liposomes consisting of phospholipids with high transition temperature could be an effective vaccine vehicle for tumor-associated antigens for inducing cell mediate immunity.
Keywords: Cancer vaccine; P5 HER2/neu peptide; cell mediated immunity; liposomes; nanoliposomes; phase transition temperature.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
- Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer.Naghibi L, Yazdani M, Momtazi-Borojeni AA, Razazan A, Shariat S, Mansourian M, Arab A, Barati N, Arabsalmani M, Abbasi A, Saberi Z, Badiee A, Jalali SA, Jaafari MR.Naghibi L, et al.PLoS One. 2020 Dec 10;15(12):e0243550. doi: 10.1371/journal.pone.0243550. eCollection 2020.PLoS One. 2020.PMID:33301467Free PMC article.
- A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.Arab A, Behravan J, Razazan A, Gholizadeh Z, Nikpoor AR, Barati N, Mosaffa F, Badiee A, Jaafari MR.Arab A, et al.J Drug Target. 2018 Apr;26(4):365-372. doi: 10.1080/1061186X.2017.1387788. Epub 2017 Oct 18.J Drug Target. 2018.PMID:28972792
- Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model.Alipour Talesh G, Ebrahimi Z, Badiee A, Mansourian M, Attar H, Arabi L, Jalali SA, Jaafari MR.Alipour Talesh G, et al.Immunol Lett. 2016 Aug;176:57-64. doi: 10.1016/j.imlet.2016.05.016. Epub 2016 Jun 1.Immunol Lett. 2016.PMID:27260485
- P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.Shariat S, Badiee A, Jalali SA, Mansourian M, Yazdani M, Mortazavi SA, Jaafari MR.Shariat S, et al.Cancer Lett. 2014 Dec 1;355(1):54-60. doi: 10.1016/j.canlet.2014.09.016. Epub 2014 Sep 16.Cancer Lett. 2014.PMID:25224570
- Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.Knutson KL, Disis ML.Knutson KL, et al.Clin Breast Cancer. 2001 Apr;2(1):73-9. doi: 10.3816/CBC.2001.n.014.Clin Breast Cancer. 2001.PMID:11899386Review.
Cited by
- Nanoparticle drug delivery systems: an excellent carrier for tumor peptide vaccines.Wang J, Hu X, Xiang D.Wang J, et al.Drug Deliv. 2018 Nov;25(1):1319-1327. doi: 10.1080/10717544.2018.1477857.Drug Deliv. 2018.PMID:29869539Free PMC article.Review.
- Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer.Naghibi L, Yazdani M, Momtazi-Borojeni AA, Razazan A, Shariat S, Mansourian M, Arab A, Barati N, Arabsalmani M, Abbasi A, Saberi Z, Badiee A, Jalali SA, Jaafari MR.Naghibi L, et al.PLoS One. 2020 Dec 10;15(12):e0243550. doi: 10.1371/journal.pone.0243550. eCollection 2020.PLoS One. 2020.PMID:33301467Free PMC article.
- Lipid Vesicles Loaded with an HIV-1 Fusion Inhibitor Peptide as a Potential Microbicide.Sánchez-López E, Paús A, Pérez-Pomeda I, Calpena A, Haro I, Gómara MJ.Sánchez-López E, et al.Pharmaceutics. 2020 May 31;12(6):502. doi: 10.3390/pharmaceutics12060502.Pharmaceutics. 2020.PMID:32486415Free PMC article.
- Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks.Fobian SF, Cheng Z, Ten Hagen TLM.Fobian SF, et al.Pharmaceutics. 2021 Dec 23;14(1):26. doi: 10.3390/pharmaceutics14010026.Pharmaceutics. 2021.PMID:35056922Free PMC article.Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous